Reska Biotech (GWIN) Stock Price
Reska Biotech Price
Revenue has compounded at 169.9% per year over the past 4 years to 5.46 M USD. Reska Biotech's net margin stands at -53.3%, down from 7.1% several years earlier. The stock trades about 560% above its 52-week low.
Reska Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Reska Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Reska Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Reska Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Reska Biotech Price |
|---|---|
| 8/6/2026 | 0.51 USD |
| 8/5/2026 | 0.51 USD |
| 8/4/2026 | 0.51 USD |
| 8/3/2026 | 0.51 USD |
| 7/31/2026 | 0.51 USD |
| 7/30/2026 | 0.51 USD |
| 7/29/2026 | 0.51 USD |
| 7/28/2026 | 0.51 USD |
| 7/27/2026 | 0.51 USD |
| 7/23/2026 | 0.51 USD |
| 7/22/2026 | 0.51 USD |
| 7/21/2026 | 0.51 USD |
| 7/20/2026 | 0.51 USD |
| 7/17/2026 | 0.51 USD |
| 7/16/2026 | 0.51 USD |
| 7/15/2026 | 0.51 USD |
| 7/14/2026 | 0.51 USD |
| 7/13/2026 | 0.51 USD |
| 7/10/2026 | 0.51 USD |
| 7/9/2026 | 0.51 USD |
| 7/8/2026 | 0.51 USD |
| 7/7/2026 | 0.51 USD |
| 7/6/2026 | 0.51 USD |
| 7/2/2026 | 0.51 USD |
| 7/1/2026 | 0.51 USD |
| 6/30/2026 | 0.51 USD |
| 6/29/2026 | 0.51 USD |
| 6/26/2026 | 0.51 USD |
| 6/25/2026 | 0.51 USD |
| 6/24/2026 | 0.49 USD |
| 6/23/2026 | 0.49 USD |
| 6/22/2026 | 0.49 USD |
| 6/18/2026 | 0.49 USD |
| 6/17/2026 | 0.49 USD |
| 6/16/2026 | 0.49 USD |
| 6/15/2026 | 0.49 USD |
| 6/12/2026 | 0.49 USD |
| 6/11/2026 | 0.49 USD |
| 6/10/2026 | 0.49 USD |
| 6/9/2026 | 0.49 USD |
| 6/8/2026 | 0.49 USD |
| 6/5/2026 | 0.49 USD |
| 6/4/2026 | 0.49 USD |
| 6/3/2026 | 0.49 USD |
| 4/9/2026 | 0.21 USD |
| 4/8/2026 | 0.76 USD |
| 3/19/2026 | 1.77 USD |
| 3/18/2026 | 1.47 USD |
| 3/17/2026 | 1.01 USD |
| 3/16/2026 | 0.53 USD |
| 3/13/2026 | 0.28 USD |
| 11/4/2025 | 0.09 USD |
| 11/3/2025 | 0.08 USD |
| 10/2/2025 | 0.10 USD |
Reska Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Reska Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|
| – | – | – | – | 3.00 | 5.00 | – |
| – | – | – | – | – | 66.67 | – |
| – | – | – | – | 1.00 | 2.00 | -2.00 |
| – | – | – | – | 33.33 | 40.00 | – |
| – | – | – | – | 1.00 | -2.00 | -2.00 |
| – | – | – | – | – | -300.00 | – |
| 0.18 | 0.18 | 0.18 | 0.54 | 18.05 | 22.68 | 77.16 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Reska Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Reska Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Reska Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Reska Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Reska Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Reska Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Reska Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Reska Biotech business model & stock analysis
Reska Biotech SWOT Analysis
Strengths
Glorywin Entertainment Group Inc possesses several strengths that contribute to its success in the industry. Firstly, the company has a diverse portfolio of entertainment offerings, including music, film, and television production, which allows it to cater to a broad audience and adapt to evolving market trends. Additionally, they have established strong relationships with well-known artists and production companies, enabling them to attract top talent and produce high-quality content. Furthermore, their extensive distribution network ensures widespread availability and exposure of their entertainment products.
Weaknesses
Though Glorywin Entertainment Group Inc has many strengths, it also faces certain weaknesses that could hinder its growth and market positioning. One major weakness is their dependence on external financing for their productions, which exposes them to the risks associated with variable interest rates and potential funding difficulties. Moreover, their reliance on a few key employees with unique expertise leaves the company vulnerable to talent attrition and potential disruptions in their operations. Additionally, they face increasing competition from other entertainment companies, which may pose challenges in maintaining their market share.
Opportunities
Glorywin Entertainment Group Inc has several opportunities to explore and capitalize on in the entertainment industry. The growing popularity of streaming platforms presents an opportunity for the company to leverage their content library and negotiate lucrative distribution deals. Additionally, expanding into emerging markets, such as China and India, can open up new revenue streams and allow them to tap into a larger audience base. Moreover, investing in technology and innovation, such as virtual reality experiences or interactive content, can enhance audience engagement and attract a younger demographic.
Threats
Despite its strengths and opportunities, Glorywin Entertainment Group Inc must also address potential threats that could impact their business. The volatility of the global economy and fluctuations in consumer spending habits pose risks to their revenue generation and profitability. Moreover, piracy and unauthorized streaming platforms continue to be a significant threat to the entertainment industry, potentially reducing their market share and revenue. Furthermore, changes in regulations and policies, such as copyright laws or content licensing agreements, can create challenges and increase operating costs for the company.
Reska Biotech Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Reska Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Reska Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Reska Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Reska Biotech stock splits
Reska Biotech Executives and Management Board
3 members · avg. age 41 · 33 % women
Management
Ms. Min Song (44)
Chief Executive Officer
Mr. Bernard Lim (38)
Chief Financial Officer, Executive Director · since 2017
Board of Directors
Mr. Ze Wu Xuan
Non-Executive Chairman of the Board · since 2016
Frequently asked questions about Reska Biotech
The business model of Glorywin Entertainment Group Inc involves operating in the entertainment industry, offering a diverse range of services. The company focuses on film and television production, talent management, music distribution, and other related sectors. With its in-house production capabilities and strategic partnerships, Glorywin Entertainment Group Inc aims to create and distribute high-quality content for global audiences. By leveraging its expertise and industry connections, the company seeks to capitalize on the growing demand for entertainment and contribute to the development of the entertainment landscape.
Glorywin Entertainment Group Inc is primarily active in the entertainment industry.
The main competitors of Glorywin Entertainment Group Inc in the market include companies like Entertainment One Ltd, Tencent Music Entertainment Group, and Netflix Inc. These companies also operate in the entertainment industry and offer various services such as music streaming, movie and TV show production, and content distribution. However, Glorywin Entertainment Group Inc sets itself apart by providing unique and diverse entertainment experiences to its customers.
Glorywin Entertainment Group Inc, founded in [year], is a renowned entertainment company operating globally. With a strong foothold in the industry, Glorywin has had an impressive journey since its inception. The company specializes in [specific entertainment sectors], offering its customers innovative and captivating experiences. Backed by a team of highly skilled professionals, Glorywin has consistently delivered quality entertainment products and services. Its commitment to excellence is evident in its successful track record and growing customer base. As a leader in the entertainment industry, Glorywin continues to push boundaries, explore new opportunities, and constantly evolve to meet the changing demands of the market.
Some significant milestones that Glorywin Entertainment Group Inc has achieved include the successful launch of several popular entertainment products and services, expansion into new markets, and strategic partnerships with renowned industry leaders. The company has experienced consistent growth in its user base and revenue, showcasing its ability to attract and retain customers. Additionally, Glorywin Entertainment Group Inc has received recognition for its innovative approach and cutting-edge technologies, positioning itself as a frontrunner in the entertainment industry. Its continuous focus on delivering high-quality experiences has propelled the company to become a prominent player in the market.
Glorywin Entertainment Group Inc is primarily present in multiple countries and regions. The company has a global presence, with significant operations in North America, Asia, and Europe. It has established a strong foothold in markets such as the United States, China, Canada, and other Asian countries. By expanding its reach internationally, Glorywin Entertainment Group Inc aims to leverage diverse consumer bases and tap into various growth opportunities. With its widespread presence and strategic approach, the company continues to strengthen its position as a leading player in the entertainment industry across multiple geographic regions.
Glorywin Entertainment Group Inc represents a commitment to excellence and innovation in the entertainment industry. Their core values include integrity, creativity, and customer satisfaction. The company's corporate philosophy focuses on providing high-quality entertainment experiences and fostering positive relationships with their clients. Glorywin Entertainment Group Inc continually strives to push boundaries, deliver captivating content, and establish itself as a leader in the industry. With its strong values and dedication to its stakeholders, Glorywin Entertainment Group Inc aims to create long-term value and sustainable growth for its investors and partners.
Converted at the current exchange rate, the Reska Biotech share trades at 0.44 EUR (0.51 USD).
Glorywin Entertainment Group Inc is a multinational company operating in various business sectors. The company is based in Canada and has subsidiaries in the USA, Europe, and Asia. The company's business model is based on three pillars: the entertainment industry, the technology sector, and real estate development. In the entertainment industry, Glorywin Entertainment Group Inc focuses on the production and marketing of music, films, TV shows, and live events. The company works closely with artists, producers, and distribution companies to produce high-quality content that is marketed worldwide. Well-known products include films such as "Guardians of the Tomb" and "The Chinese Widow." In addition to the entertainment industry, the company is also active in the technology sector. Glorywin develops and markets solutions in artificial intelligence, big data, and cloud computing. The company offers end-to-end solutions for businesses looking to optimize their processes and increase efficiency. Glorywin Entertainment Group Inc utilizes innovative technologies such as blockchain and IoT. Real estate development is another area of focus for the company. Glorywin concentrates on the construction and marketing of residential and commercial properties in Asia. With years of experience in real estate development, the company has successfully completed numerous projects in the past. In addition to the mentioned business sectors, Glorywin Entertainment Group Inc is also active in finance and investment. The company offers financial services and invests in promising start-ups and companies. The company pursues a comprehensive growth strategy and continuously expands into new markets and business sectors. Glorywin Entertainment Group Inc believes in partnerships with other companies to create synergies and optimize its own business activities. Overall, Glorywin Entertainment Group Inc offers a wide portfolio of products and services tailored to the needs of customers worldwide. The company combines innovative technologies with extensive industry experience to successfully operate in the market.
The revenue cannot currently be calculated for Reska Biotech.
The profit cannot currently be calculated for Reska Biotech.
The P/E ratio cannot be calculated for Reska Biotech at the moment.
The P/S cannot be calculated for Reska Biotech currently.
The Eulerpool Quality Score for Reska Biotech is 1/10.
The ISIN of Reska Biotech is US37961Q1013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Reska Biotech is GWIN. The ticker symbol is used to trade Reska Biotech shares on the stock exchange.
Reska Biotech paid dividends every year for the past 0 years.
Reska Biotech is assigned to the 'Cyclical consumption' sector.
The dividends of Reska Biotech are distributed in USD.
Reska Biotech stock
Reska Biotech Peer Group
Reska Biotech FIGI
All fundamentals and in-depth analysis of Reska Biotech
Our stock analysis for Reska Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Reska Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.